Merck Millipore Completed Acquisition of Microbiology Business of Biotest AG
Merck Millipore announced that it has completed the acquisition of the microbiology business of Biotest AG, Dreieich, Germany. All relevant authorities approved the sale of Biotest´s woldwide Microbiological Monitoring business activities, which consist of the product portfolio of Hycon (hygiene monitoring based in Dreieich) and the product portfolio of heipha Dr. Müller GmbH (microbiological culture media and microbiological test systems, based in Eppelheim, Germany) to Merck. Merck and Biotest today closed the transaction, which was agreed upon in March 2011.
The acquired businesses will add to Merck Millipore’s existing dehydrated cell-culture media and testing systems, the so called “ready-to-use” culture media and instruments. The products are primarily used in the pharmaceutical, food & beverage, and personal-care industries.
The acquisition allows the Merck Millipore division to complement its product portfolio in the attractive growth segment industrial microbiology for contamination detection.
The acquired activities will be integrated into Merck Millipore’s Lab Solutions business unit.
“With the microbiology business of Biotest we acquire a business with a motivated, customer-oriented workforce, unique know-how and state-of-the-art production facilities in a strongly growing segment,” said Klaus Bischoff, Head of the Lab Solutions business unit within Merck Millipore. “I am excited that we could close the deal in such a short time and I warmly welcome each of the 300 new colleagues.”
“Through this acquisition we expand our portfolio and there are also many synergies in production, product and market development and – important to both companies - customer collaboration,” said Roland Heinrich, Head of Merck Millipore’s Biomonitoring business. “In addition to Ready-to-Use media, it will also add particle counting and strengthen air monitoring in our hygiene monitoring portfolio.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Wild potato germplasm holds key to disease resistance
Slim and potent - with side effects - Food supplements for weight loss or enhancing sexual performance can contain illegal active ingredients
EGene Inc. Announces Its Strategic Full-Service Distribution Alliance with AH Diagnostics of Denmark
Global Bioenergies announces break-through in direct biological production of butadiene
DSM receives grant of US Department of Energy for biotechnology research
Norwood_(charity)

Schizophrenia manifests itself in the brain structure - The symptoms of schizophrenia vary greatly from person to person

ImageBiopsy Lab - Wien, Austria
Eppendorf grows faster than the market
La Jolla Institute finds previous seasonal flu infections may provide some level of H1N1 immunity

Sequential antibiotic therapy in the laboratory and in patients - Rapid switching between different antibiotics could prevent the evolution of resistance and lead to successful treatment of patients
